The Pancare Foundation Releases a Research Framework for Pancreatic Cancer
Pancare has developed a research framework that will be used to inform decisions regarding the funding of national pancreatic research initiatives to achieve significant increases in survival rates for pancreatic cancer.
Pancreatic cancers are a group of heterogeneous diseases of both the endocrine and exocrine pancreas. Pancreatic ductal adenocarcinoma (PDAC), an exocrine tumor, represents over 90% of all pancreatic malignancies1.
The Australian Institute of Health and Welfare estimated the number of new cases of pancreatic cancer diagnosed in 2016 in Australia to be 3123 and the chance of surviving five years 7%2.
In 2014 the American National Cancer Institute (NCI) and the National Institute for Health (NIH) developed a scientific framework for PDAC aimed at improving the outlook for Americans with pancreatic ductal adenocarcinoma (PDAC) and for those at high risk of developing PDAC.
Pancare is committed to increasing the survival rate of pancreatic cancer and has therefore developed a research framework to guide our investment in research. The framework will be used to inform decisions regarding the funding of national pancreatic research initiatives to achieve significant increases in survival rates for pancreatic cancer.
Seven general areas of PDAC research are recommended (not in any order of importance);
- Understanding the biological relationship between PDAC and diabetes mellitus
- Improving early detection of PDAC through identification of biomarkers and investigating and evaluating screening protocols for early detection of PDAC and its precursors
- Studying new therapeutic strategies in immunotherapy
- RAS/KRAS dependent signaling pathways
- Targeting the surrounding tissue of the tumour – the stroma
- Development of personalized medicine strategies
- Developing strategies to reduce variations in pancreatic cancer care
You can read the full framework here.
- Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399-405.
- AIHW. Pancreatic cancer (AIHW). In: AIHW, ed. Canberra 2016:http://www.aihw.gov.au/cancer/pancreatic/.